Results 101 to 110 of about 6,404 (193)

Risk of Guillain-Barre\u301 syndrome (GBS) following recombinant zoster vaccine (RZV)

02-Zoster-Vaccines-Forshee ...

core  

Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial

Human Vaccines & Immunotherapeutics
Phase III multi-country studies (ZOE-50/70) demonstrated that the adjuvanted recombinant zoster vaccine (RZV) was well tolerated and prevented herpes zoster (HZ) in healthy ≥ 50-year-olds, with a vaccine efficacy (VE) > 90% across age groups.
Diana Alexandra Echeverria Proano, Fengcai Zhu, Xiaodong Sun, Jesús Zoco, Jyoti Soni, Neeraj Parmar, S. Omar Ali   +6 more
doaj   +1 more source

Construction, stability and immunogenicity of recombinant BCG expressing HIV-1 subtype C gag under the control of MtrA promoter, with or without the leader sequences

, 2011
This study aimed to compare recombinant mycobacteria expressing HIV-1 gag under the control of different promoters and leader sequences. This was done to determine whether the genetic stability of the recombinant mycobacteria could be improved by ...
Lebeko, Maribanyana R
core  

The Effectiveness of Recombinant Zoster Vaccine: Observations in the Wild

Clinical Infectious Diseases, 2021
openaire   +2 more sources

Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses

npj Vaccines
Herpes zoster (HZ), also known as shingles, is caused by the reactivation of latent varicella-zoster virus (VZV). Decreased VZV-specific T-cell immune responses significantly contribute to the development of HZ.
Soo-Kyung Jeong, Su-Jin Ham, Seung-Hee Baek, Eun-Jung Jung, Hyun-Jin Jo, Hye-Ran Cha, Jae-Myun Lee, Byung Cheol Ahn, Jung Sun Yum, Eunyoung Chun   +9 more
doaj   +1 more source

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) \u2014 United States, October 2017\u2013June 2018: Supplementary Table 1. Search Strategy to Identify Recombinant Zoster Vaccine (RZV) Reports of Selected Pre-specified Outcomes in the Vaccine Adverse Events Reporting System (VAERS) \u2014 United States, October 2017\u2013June 2018 [PDF]

Supplementary Table for: Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) \u2014 United States, October 2017\u2013June ...

core  

Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations.

ImportanceHerpes zoster infection is common in immunocompromised individuals. Recently, the Advisory Committee on Immunization Practices recommended immunizing with the recombinant zoster vaccine (RZV).ObjectiveTo evaluate the efficacy, immunogenicity ...
Michael Yip, Nirma Khatri Vadlamudi, Fawziah Marra, Jacquelyn J Cragg   +3 more
core   +1 more source

Zoster-Like Dermatomal Eruption Following Recombinant Zoster Vaccine: A Case Report. [PDF]

Cureus
AlZahrani RM, Alsulami AH, Khan ZH, Kokandi AA, Shaikh RM.   +4 more
europepmc   +1 more source

Immune Response to an Adjuvanted Recombinant Zoster Vaccine in Japanese Patients with Rheumatoid Arthritis Receiving Upadacitinib (End Zoster-J Study): Study Protocol for an Exploratory Parallel Triple-Arm Prospective Trial

Background: Janus kinase (JAK) inhibitors have emerged as a new class of disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis (RA).
Masao Katsushima, Kazuo Fukumoto, Ryu Watanabe, Kenji Mamoto, Hisako Fujii, Tadashi Okano, Motomu Hashimoto, Takumi Imai, Yuki Furusawa, Yutaro Yamada, Shinsuke Yamada   +10 more
core   +1 more source

Recombinant zoster vaccine is associated with a reduced risk of dementia. [PDF]

Nat Commun
Rayens E, Sy LS, Qian L, Ackerson BK, Tubert J, Luo Y, Modha PP, Calderon RO, Chmielewski-Yee E, Oraichi D, Yun H, Koro C, Tseng HF.   +12 more
europepmc   +1 more source